ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Amarin Corp PLC

Amarin Corp PLC (AMRN)

0.8593
-0.0125
(-1.43%)
At close: April 19 4:00PM
0.8651
-0.0067
( -0.77% )
After Hours: 5:31PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.8651
Bid
0.865
Ask
0.885
Volume
1,024,842
0.86 Day's Range 0.8858
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.8718
Open
0.87
Last Trade
20
@
0.885
Last Trade Time
18:13:05
Financial Volume
$ 899,811
VWAP
0.878
Average Volume (3m)
-
Shares Outstanding
-
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Amarin Corp PLC

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa. Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
London, Gbr
Founded
1970
Amarin Corp PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AMRN. The last closing price for Amarin was $0.87. Over the last year, Amarin shares have traded in a share price range of $ 0.00 to $ 0.00.

Amarin currently has 0 shares outstanding.

AMRN Latest News

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President...

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic...

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Canada NewsWire TORONTO, April 8, 2024 Findings Presented...

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American...

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European...

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting --    DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSLRComplete Solaria Inc
$ 0.659
(46.44%)
6.62M
MNDRMobile health Network Solutions
$ 36.05
(32.20%)
1.01M
OMHOhmyhome Ltd
$ 0.6299
(28.55%)
68.74k
TTOOT2 Biosystems Inc
$ 3.79
(28.04%)
399.27k
OLBOLB Group Inc
$ 0.39
(18.18%)
1.25M
VAXXVaxxinity Inc
$ 0.2506
(-47.36%)
433.81k
HEPAHepion Pharmaceuticals Inc
$ 1.40
(-30.35%)
98.5k
LGHLLion Group Holding Ltd
$ 0.621
(-15.50%)
163.54k
CCLDCareCloud Inc
$ 1.00
(-12.28%)
1.23k
CRMLCritical Metals Corporation
$ 7.15
(-11.73%)
1.93k
CSLRComplete Solaria Inc
$ 0.659
(46.44%)
6.62M
EGOXNext e GO NV
$ 0.046
(-10.16%)
2.98M
BSFCBlue Star Foods Corporation
$ 0.084
(10.53%)
2.8M
GDHGGolden Heaven Group Holdings Ltd
$ 0.249
(5.96%)
2.33M
SINTSiNtx Technologies Inc
$ 0.0409
(-2.15%)
2.04M

AMRN Discussion

View Posts
ziploc_1 ziploc_1 2 hours ago
DMC8...."In Hikma’s press release Hikma refered to multiple uses of generic Vascepa....Amarin's lawyer emphasized that physicians observed Hikma’s press release and saw that its drug was the generic equivalent of Amarin’s drug. This, the lawyer argued, creates a question for the jury of inducement of infringement."

Why would Hikma NOT disclose on their generic meds' label that "this med is ONLY to be used for treatment of patients with triglycerides of over 500 mgs/dcl"?...The obvious answer is that Hikma would NEVER do this because...if they informed patients and Docs of that uncomfortable but legal fact, they would then lose 97% of the generic EPA's market share for the U.S.,which they now pull in by infringing on Amarin's CVD patents and which 97% of market share should, by law, be going to Vascepa.
👍️ 2
ramfan60 ramfan60 2 hours ago
Yes, we knew this was coming...... so no surprise there
👍️0
RobinF RobinF 2 hours ago
Thanks, Michael.
👍️0
hayward hayward 2 hours ago
RobinF

Looks like they all received 180,000 at .87 Options and 50.000 free shares no wonder they stepped on the PPS IMO up on monday

Michael
👍️0
roadkilll roadkilll 2 hours ago
Buy back as much as possible before announcing a marketing partner in Europe.
Big Pharma needed to get attention to docs letting CV patients leaving the hospital that need add on protection to prevent that second event.
"The total events were significantly reduced by approximately 35% with icosapent ethyl in individuals with prior MI who are at elevated risk of another major event."
.
It is truly malpractice not to give your patient the option of add on protection. Hundreds of thousands of patients yearly would be in the high uptake category. 100% sure Amarin does not have what is needed for effective marketing.
👍️0
RobinF RobinF 2 hours ago
Any idea what’s going on with the Form 4s?
👍️0
ramfan60 ramfan60 2 hours ago
Form 4 overload
👍️0
seve333 seve333 4 hours ago
That would be really relly disappointing to have a bad earnings report a year after they took over the company. Not sure how you build any momenteum when the earnings go the wrong way. But they did not pre release so that tells me it might not be good. If earnings are bad they will need the buyback to just keep the stock over a buck imo bad earnings usually amount to like a 30% drop for amrn.

Plus its not like it would be some earth shattering PR pretty much everyone knows it was going to be approved.
👍️0
DAR53 DAR53 5 hours ago
They could be saving it for the ER to buffer any negative tones re. revenue, etc.
👍️0
Meowza Meowza 6 hours ago
"Generic Lovaza is the same thing."
👍️0
rosemountbomber rosemountbomber 7 hours ago
Well you used the word purify, which of course you need to do if you want to concentrate it.
👍️0
seve333 seve333 8 hours ago
Why have the not announced if the buyback was approved yet? I assume it was but AMRN always seems to be lacking in PR's
👍️0
OracleCentaur29 OracleCentaur29 8 hours ago
https://pubmed.ncbi.nlm.nih.gov/17941053/
Discusses Eicosapentaenoic acid aka Vascepa
And regeneration of myelin which affects the brain. Myelin is like insulation/wiring in the brain.Many diseases like MS and a disease my grandson has called leukodystrophy need a solution for myelin regeneration or stabilization of existing myelin.
👍️0
Triple88 Triple88 9 hours ago
🙂👏👏
👍️0
CaptBeer CaptBeer 9 hours ago
I'm working on it!
👍️ 1
CaptBeer CaptBeer 9 hours ago
DYK the use of IPE (VASCEPA/VAZKEPA) was associated with CVD RR regardless of baseline LDL-c or Lp(a), or even TG levels? Why is that? It's the EPA Stupid.@PamTaubMD @CBallantyneMD @ErinMichos @SABOURETCardio @AAgarwalaMD @gabrielsteg @mmillermd1 @DLBHATTMD @VietHeartPA pic.twitter.com/6cfXVrJrYI— Mike Everts (@GeoWizz_) April 19, 2024
👍️ 1
Triple88 Triple88 9 hours ago
Excellent Chart !!
Now we just need Dr's in EU to begin prescribing with haste and abundance !!
👍️0
DMC8 DMC8 9 hours ago
Same for AMRN?
👍️0
CaptBeer CaptBeer 10 hours ago
FYI: I've updated my REDUCE-IT SG analysis slide to include the two new studies presented at ACC24 last week.
ENJOY!
👍️ 2
DMC8 DMC8 10 hours ago
Consider this for AMRN?

https://www.cnbc.com/2024/04/19/trump-media-alerts-nasdaq-to-potential-market-manipulation-from-short-selling.html?__source=iosappshare%7Ccom.google.chrome.ios.OpenExtension
👍️0
Tatsumaki Tatsumaki 10 hours ago
but neglect to mention that the other reason is that it is almost impossible to significantly concentrate the EPA as long as the fatty acid is still bound to the glycerol.

You didn't read the 2nd paragraph I wrote? Like when I say raw fish oil trigs have a mix of fa's on the glycerol so you cant concentrate the trigs and only way is to break down into individual fa's to exclude DHA and other fa's and get the concentration high enough? You neglected to comprehend.
👍️0
ziploc_1 ziploc_1 10 hours ago
"Amarin has secured a worldwide patent priority claim to a LYMPH-RELEASING composition of eicosapentaenoic acid ethyl ester (LR-EtEPA) technology/invention and methods of using the same to increase EPA uptake in tissues to treat and/or prevent the onset of a number of diseases including:
- Cardiopulmonary, cardiovascular, and cerebrovascular diseases
- Pulmonary disease including sepsis, SIRS, and/or ARDS
- Neurological diseases
- Cancer...including cancers associated with the lymphatic system"(e.g. LYMPHOMAS)

I would hope that some mention of this product will be made by CEO Holt at the Amarin upcoming Q4 2023 results C.C. on 5/2/24
👍️ 1
rosemountbomber rosemountbomber 11 hours ago
Thanks for catching that and correcting the "huge". You discuss the need for separating from the glycerol in order to purify the EPA, but neglect to mention that the other reason is that it is almost impossible to significantly concentrate the EPA as long as the fatty acid is still bound to the glycerol. Good explanation on the purification.

You raise a good point about why the FDA has not gone after some of the supplement manufacturers. Of course the supplement manufacturers were selling omega-3 products long before any approved drugs came out, BUT although I am not sure, those products were confined to simply fish oil and were limited by the fact that they comprised no more than 18% EPA and 12% DHA. I remember after Lovaza was on the market that suddenly we began seeing higher concentration omega-3 products come on the supplement market. So I don't really know the timing of when supplement manufacturers started using the ethylated products - before or after FDA approval of Lovaza. But that timing might be an explanation as to why the FDA is not clamping down.
👍️0
DMC8 DMC8 14 hours ago
“In April 2024, Amarin (NASDAQ: AMRN) Corporation plc showcased two data presentations at ACC.24 which describe the impacts of VASCEPA ®/VAZKEPA ® on decreasing adverse cardiovascular events in patients with reduced lipoprotein level or baseline high and decreases the risks of cardiovascular diseases.”
https://www.precedenceresearch.com/lipid-lowering-drugs-market
👍️ 1
DMC8 DMC8 14 hours ago
REDUCE-IT Analysis Outlines Benefit of Icosapent Ethyl Across Range of LDL-C Levels
Apr 18, 2024
https://www.hcplive.com/view/reduce-it-analysis-outlines-benefit-of-icosapent-ethyl-across-range-of-ldl-c-levels
👍️0
Tatsumaki Tatsumaki 16 hours ago
by detaching the EPA from the huge glycerol portion of the triglyceride molecule
Glycerol is not huge... it's a 3 carbon chain with hydroxyls on each carbon. A triglyceride is a glycerol backbone with a fatty acid (3) linked to each carbon. Thus a tri-glyceride. Trying to get rid of a bulky glycerol isnt why ethylation is done.

The actual reason they separate the 3 fatty acids from the glycerol and ethylate the individual fa's is in unrefined fish oil there can be any combination of fatty acids found on the glycerol backbone. It's not all EPA on one trig molecule, all DHA on another etc... cant purify trigs as it's variable combos on each plus some other stuff like DPA, ALA, and shorter chain stuff. So they have to break it all down into individual free fatty acids in order to fractionate and purify those individual fatty acids into separate products. Ethylation stabilizes the molecule during and after the process. It's the only way any refined fish oil supplement or drug can hit the higher purities needed and exclude DHA and others trace fa's. Legally, the supplement makers should re attach the purified EPA back on to a glycerol to form an EPA only triglyceride that they label as rTG... but the intermediate step in doing that is still the same E-EPA process driven to the desired purity taken one more step.

Incidentally the MAG-EPA discussed a few times is just the glycerol backbone one EPA stuck to it... the other 2 carbons just have the hydroxyl group. DAG-EPA would have 2 EPA, and one hydroxyl. Seems like lots of ways for people to get "its the EPA stupid" in the US that don't funnel into Amarin's bottom line and stock price.

The question you should all be asking is why isn't the FDA addressing supplements containing E-EPA as it's an actual registered drug product. Normally they go nuts if a supplement contains an API and pursue action aggressively. They have to protect their drug approval racket or people wont pay for the mafia protection and exclusivity if there is none. They went after and banned red rice yeast supplements cause they had the og statin in trace levels after statins hit the market. Yet they're pretty quiet with multiple supplements using ethylated EPA. Everyone sweating generics when many like Jroon aregetting off the chart blood levels delivered right to their door with no Rx needed.
👍️ 3
Whalatane Whalatane 18 hours ago
Thx Laurent
Re your view one more real world data set in the form of MITIGATE and that should be all the additional evidence we need for Germany/France
Love your optimism but unfortunately don't share it .
Will be happy to be proven wrong.

The conclusion of the poster ... " Follow up studies with larger sample sizes ..."etc . Why Amarin does not some how independently fund those ...rather the wasting $ in a stock buy back ...is beyond me .

Fund as per the MITIGATE design ...where as the PI's have complete control of design , analysis , data release etc

Kiwi
👍️0
DMC8 DMC8 18 hours ago
https://fedcircuitblog.com/2024/04/17/argument-recap-amarin-pharma-inc-v-hikma-pharmaceuticals-usa-inc/
👍️ 2
Number sleven Number sleven 20 hours ago
North, I think my debate with stockboy has come to a conclusion. I would be interested to hear your thoughts about the effects of a remand in the Hikma inducement case. If my math is correct, treble damages could be more than the current Market cap of Hikma corporation.
Sleven,
👍️0
dogn dogn 20 hours ago
Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Investigators and others think it might be time for everybody in the US to have their Lp(a) screened at least once in a lifetime.

https://www.tctmd.com/news/lpa-linked-higher-ascvd-risks-diverse-patient-groups
👍️0
north40000 north40000 20 hours ago
Let’s continue this debate tomorrow. We don’t seem to have helped Amarin share price today. I just received a news alert about an explosion at an Iran oil refinery. That news may have a further negative effect on all sectors of the market tomorrow but for the defense industry sector.
👍️0
dogn dogn 20 hours ago
High on Lipoprotein-

https://www.jacc.org/jacc-edge/current

You know you are at a cardiology conference when the busiest booth isn’t the one providing free ice cream, but the one offering complimentary Lp(a) screenings. Likely the greatest concentration of lipid-obsessed people in one room, ACC.24 was constantly buzzing with discussion of Lp(a) and its ramifications for patient care. Elevated Lp(a) levels confer greater cardiovascular risk even when LDL levels are optimal and are not affected by current therapeutic options. The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial) trial aimed to assess the benefit of icosapent ethyl (IPE) across a range of Lp(a) levels. Nearly 7,000 patients on statin therapy with CV disease were randomized to receive IPE or placebo, had a baseline Lp(a) level assessed, and followed for any major adverse CV events. While IPE did not directly lower Lp(a) levels, the study demonstrated that IPE consistently decreased the occurrence of major CV events, irrespective of the actual Lp(a) level. Additional studies will be needed to better understand how to best address this risk factor.
👍️0
rosemountbomber rosemountbomber 21 hours ago
When the FDA checks the Generics for bioavailability, they are checking for EPA not the ethyl ester form. It is absorbed as EPA. Active moiety as Sleven said, but you seem to disregard this.

Think of say, the blood pressure drug, Metoprolol. It is available as Metoprolol tartrate and metoprolol succinate, with the succinate form having greater liposolubility.

https://pubmed.ncbi.nlm.nih.gov/20638827/

"The use of marine n-3 polyunsaturated fatty acids (n-3 PUFA) as supplements has prompted the development of concentrated formulations to overcome compliance problems. The present study compares three concentrated preparations - ethyl esters, free fatty acids and re-esterified triglycerides - with placebo oil in a double-blinded design, and with fish body oil and cod liver oil in single-blinded arms. Seventy-two volunteers were given approximately 3.3g of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) daily for 2 weeks. Increases in absolute amounts of EPA and DHA in fasting serum triglycerides, cholesterol esters and phospholipids were examined. Bioavailability of EPA+DHA from re-esterified triglycerides was superior (124%) compared with natural fish oil, whereas the bioavailability from ethyl esters was inferior (73%). Free fatty acid bioavailability (91%) did not differ significantly from natural triglycerides. The stereochemistry of fatty acid in acylglycerols did not influence the bioavailability of EPA and DHA."
👍️0
Laurent Maldague Laurent Maldague 21 hours ago
Just an FYI regarding the P-value, the VA study had a P value < .05, it's implied by the 95% confidence intervals. (95% CI .56 - .69) They should be able to easily produce the P value if in the actual publication.


Regarding Kaiser, one more real world data set in the form of MITIGATE and that should be all the additional evidence we need for Germany/France.
👍️ 1
Mr Stockboy Mr Stockboy 21 hours ago
dear friend, we are all on the same page...

You have just given a patent reason why Amarin patented E-EPA if I repeat your post "it is the way they can concentrate enough EPA to get 1,000mg into a swallowable pill." If I agree/submit without agreeing to your assertion why Vascepa is E-EPA and not EPA, you actually proved why Amarin lawyers should be defending E-EPA in the court of law.

All the best.
👍️0
rosemountbomber rosemountbomber 21 hours ago
I like your tenacity but I have to agree with Sleven on this. The reason for ethyl ester being in the patents, is that it is the way they can concentrate enough EPA to get 1,000mg into a swallowable pill, by detaching the EPA from the huge glycerol portion of the triglyceride molecule.
👍️0
Whalatane Whalatane 21 hours ago
Always ...I'm long AMRN with average purchase price of around $1
I also take Vascepa
Why am I long AMRN ? In the hope that Sarissa et al will eventually get their act together ( besides cost cutting and cash flow management ) and generate some data that will convince Germany and France to reimburse for Vazkepa .
More Real World data such as we recently saw from the VA is what I want to see. Larger studies with P values .
Look at some of the sub groups listed by poster Capt.
Revascularisation rates for those on a Statin plus V vs Statin alone were dramatically lower for those on Statin plus V . Kaiser and the VA must have a ton of data on this by now.
The buy back is a dumb idea IMHO ...simply to make disgruntled share holders feel better .
I expect both Zip and I will either be 6 ft under ( or ash's in the wind ) before AMRN makes any significant $ out of China
So cheer up Always ...you aren't the only one currently losing $ on their AMRN position
Kiwi
👍️0
FlyFishingStocks FlyFishingStocks 21 hours ago
Today's bearish engulfing candle is forecasting yearly lows in a matter of days.



Just as predicted, the triple top breakdown part 2 is behaving as it did in the previous year; trending towards a new low. The false upside breakout above the ice line has traced yet another triple top part 3 leading to another leg down. The pattern is so simple a cave man could trade it.
The nasty sell off in small caps and bios will only accelerate /amplify the slide. Got TA??
👍️0
Number sleven Number sleven 22 hours ago
Stockboy, That's fine with me. You should start a letter writing campaign with the lawyers that represent Amarin. Clearly you understand the law and biochemistry at a level they can't comprehend.
Sleven,
👍️ 1
Mr Stockboy Mr Stockboy 22 hours ago
Aha! You actually prove my argument if you are correct and I won't debate that now.

Amarin "discovered" E-EPA was necessary, and no prior art addressed this. NONE.

Amarin discovered E-EPA was a necessary step to induce EPA into the body (your insight). Amarin clearly understood pre- and phase 1 studies EPA alone could not be put into a capsule in comparison to E-EPA which via efficacy and safety achieved the desired outcome.

E-EPA is not EPA. Fact. You are better educated than me, but E-EPA and EPA are not the same. Tell everyone on IHUB they are the same... you won't, you know the truth. Let's work together my friend.
👍️0
Number sleven Number sleven 22 hours ago
Stockboy, I understand why you disagree, and I respect your passion. But you are not correct. Icosapent ethyl is no longer an ethyl ester at the point where it is absorbed by the body.
Sleven,
👍️0
Mr Stockboy Mr Stockboy 22 hours ago
I think this discussion is necessary, but I disagree with the suggestion "EPA is the active moiety" and could not be affected negatively or positively by turning it into an ethyl ester. Amarin had clear reasons for turning it into an ethyl ester and every patent going back to the beginning, states E-EPA.

IHUB friends: Any change in the chemical chain is the basis for the patent Amarin claimed. Amarin claimed E-EPA, not EPA. For some patented reason, Amarin determined adding the Ester Ethyl was necessary, and every since has cited it in every claim section of patents. The fact is turning EPA into E-EPA is not a mote "moiety" point. There are efficacy issues, safety issues, a lot of issues!!!!

In court, Amarin is there to defend E-EPA.
👍️0
Mr Stockboy Mr Stockboy 22 hours ago
I entirely disagree (respectfully).

Amarin altered in the lab EPA into E-EPA for a valid, patented reason. They in the patents even cite other possible indications. Keep in mind number sleven, E-EPA, a chemical composition could have negatively or positively affected the EPA moiety. Amarin clearly did early studies which led them to the Ethyl Ester version, and for a REAL reason.

In a court of law, a lawyer, an astute lawyer would have argued EPA is not E-EPA, as the chemistry is not the same, and it's not the same. If you cannot see how a lawyer cannot argue EPA is not E-EPA, then I wonder in due respect. A Lincoln is not a Mercury though made by the same firm.

Hikma lawyers focused on the prior art of EPA, not E-EPA. I think Marjac would side with me, as would other lawyers. But let's keep the discussion going. All the best!
👍️0
CaptBeer CaptBeer 22 hours ago
You can review the 6 MARINE Patents in the Nevada Case here:
https://drive.google.com/drive/folders/195jJTfioM-ljaGgtLKfddWukNTAl-u1j?usp=sharing
👍️0
DMC8 DMC8 22 hours ago
Q: What is the CV benefit of icosapent ethyl across a range of Lp(a) levels?

A: Icosapent ethyl was associated with reduced MACE outcomes across a range of Lp(a) levels

Read more in #JACC: https://t.co/YpXHlljxqN #cvPrev pic.twitter.com/bg21Pqahto— American College of Cardiology (@ACCinTouch) April 18, 2024
👍️0
Number sleven Number sleven 22 hours ago
Stockboy, EPA is the active moiety. Legally it doesn't matter that icosapent ethyl is an ethyl ester of that moiety. The same thing would apply to a self emulsifying variation. The active part of the molecule, that relates to medical benefits, is EPA. A patent on a self emulsifying version would prevent the generic companies from selling their own version. It doesn't have a legal effect on prior art.
Sleven,
👍️0
Mr Stockboy Mr Stockboy 22 hours ago
It's embarrassing (and costing all of us billions) but Amarin, its opponents (maybe knowingly), and naive non-chemist judges... WELL GANG, they've all been arguing over the wrong chemistry. FACT: Vascepa is not EPA. Vascepa is E-EPA. Eh Marjac? Eh Amarin? Eh Holt?

I know enough that ethyl ester was added for a patent-safety-efficacy reason. Bank on it. And here's the fact Jack: there is no prior art like Mori focused on E-EPA, otherwise prove me wrong.
👍️0
Mr Stockboy Mr Stockboy 22 hours ago
Amarin Needs to Defend the Right Molecule in Court: E-EPA (C22H34O2).

All of Amarin's patents claim E-EPA.

In Nevada, Amarin argued with Hikma over EPA (prior art). Big glaring mistake!

E-EPA is a novel, lab created, molecule, not found in fish oil.

Hopefully, there is time and opportunity for Amarin to return to court and defend E-EPA, not EPA.
👍️ 1
Mr Stockboy Mr Stockboy 23 hours ago
Catch this every claim section of Vascepa patents are E-EPA, not EPA. EVERY PATENT, EVERY! E-EPA

8557280 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
8557799 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
8518929 Methods of treating hypertriglyceridemia
8524698 Methods of treating hypertriglyceridemia
8546372 Methods of treating hypertriglyceridemia
8551521 Stable pharmaceutical composition and methods of using same
...ALL THE WAY INTO THE PRESENT. E-EPA.

Amarin is in court to defend E-EPA, not EPA. Again, Amarin had patent reasons for adding ethyl ester. There is no prior art focused on E-EPA. I sure hope someone is listening at Amarin.



👍️ 1
Mr Stockboy Mr Stockboy 23 hours ago
Patent 11690820 "4. The composition of any one of claim 1, 2, or 3 wherein the ethyl-eicosapentaenoic acid is present in the composition in an amount of 250 mg to 1000 mg. 5. A pharmaceutical composition comprising 250 mg to 1000 mg of fatty acids at least 95% of which are in the form of ethyl eicosapentaenoic acid, wherein the composition contains no docosahexaenoic acid, and the composition is present in a capsule. 6. A pharmaceutical composition comprising 250 mg to 1000 mg of fatty acids at least 95% of which are in the form of ethyl-eicosapentaenoic acid, wherein the composition contains (a) less than 5% in aggregate of arachidonic acid and n-3 docosapentaenoic acid, and (b) no docosahexaenoic acid; and wherein the composition is present in a capsule."

Patent 8557280 "1. A method of reducing triglycerides in a subject in need thereof who is on statin therapy comprising, administering to the subject 2500 mg to 5000 mg per day of ethyl eicosapentaenoate for a period effective to reduce triglycerides in the subject. 2. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 500 mg to about 1.5 g of ethyl eicosapentaenoate 4. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 900 mg to about 1 g of ethyl eicosapentaenoate. 6. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 1 g of ethyl eicosapentaenoate. . The method of claim 1 wherein the ethyl eicosapentaenoate is present in a pharmaceutical composition comprising other fatty acids or esters thereof and said ethyl eicosapentaenoate comprises at least about 90%, by weight, of the fatty acids present in the composition."

Patent 8557799 "3. The method of claim 2 wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting VLDL-C compared to a fasting VLDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 4. The method of claim 3, wherein upon administering the composition to the subject daily for said period, the subject exhibits at least a 15% reduction in fasting triglycerides compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 5. The method of claim 4, wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting LDL-C compared to a fasting LDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. . A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl and a fasting LDL-C level of about 40 mg/dl to about 100 mg/dl comprising, orally administering to the subject daily for a period of at least about 4 weeks a pharmaceutical composition comprising about 4 g of ethyl-EPA and not more than about 4% DHA or its esters, by weight of all fatty acids present. 10. The method of claim 9 wherein upon administering the composition to the subject for said period, the subject exhibits a reduction in fasting non-LDL compared to a fasting non-LDL level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 11. The method of claim 9 wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting VLDL-C compared to a fasting VLDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 12. The method of claim 9 wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting non-HDL-C compared to a fasting non-HDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 13. The method of claim 9 wherein upon administering the composition to the subject daily for said period, the subject exhibits a reduction in fasting total cholesterol compared to a fasting total cholesterol level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. 14. A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl comprising, administering orally to the subject on statin therapy a pharmaceutical composition comprising about 4 g per day of ethyl-EPA and not more than about 4% DHA or its esters, by weight of all fatty acids present, for a period of at least about 4 weeks thereby to lower fasting triglycerides in the subject by at least 15% compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period, and wherein administration of the composition results in a statistically significant reduction in fasting LDL-C compared to a fasting LDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period. "

It's E-EPA, Amarin has a clear path to reinstate the patents.
👍️ 2

Your Recent History

Delayed Upgrade Clock